Phase 2 Ovarian Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older
• People diagnosed with high-grade serous ovarian cancer, fallopian tube cancer, or primary peritoneal cancer
• People whose tumor testing (which can be done on stored tissue samples) shows a positive result for a protein called Cyclin E1, measured using a specific test provided by the trial sponsor
• People whose cancer has stopped responding to platinum-based chemotherapy (known as platinum-resistant disease)
• People who have received between 1 and 3 previous treatment regimens (or 1 to 4 if prior treatment included a drug called mirvetuximab), depending on which part of the trial applies (confirm with trial site)
• People in one specific group (Part 2c) who may have had 1 to 4 prior treatment regimens and have previously received a weekly taxane-based treatment (confirm with trial site)
• People who have previously received bevacizumab, if that treatment was considered appropriate for them under standard medical care
• People who have previously received a PARP inhibitor, if they carry a BRCA 1 or 2 gene mutation or a related DNA repair issue, and if that treatment was considered appropriate under standard medical care
• People who have previously received mirvetuximab, if that treatment was considered appropriate for them under standard medical care
• People whose cancer can be measured on scans according to standard criteria (RECIST v1.1)
• People whose blood counts and organ function meet the levels specified in the trial protocol
• People with a good general performance status, able to carry out normal daily activities with little or no restriction (ECOG score of 0 or 1)

Who may not be able to join:

• People whose cancer never responded to platinum-based chemotherapy from the very beginning (primary platinum-refractory disease)
• People whose ovarian cancer is of a different type, such as endometrioid, clear cell, mucinous, sarcomatous, mixed, low-grade, borderline, or other non-qualifying tumour types
• People who have had major surgery within the 28 days before starting the trial
• People who have been hospitalised within the 14 days before starting the trial
• People who have received chemotherapy or targeted cancer treatment within 21 days (or within 5 half-lives of the drug, whichever is shorter) before starting the trial
• People who have received radiation therapy within 21 days before starting the trial
• People who have had a stem cell transplant (their own or a donor's) within the 3 months before starting the trial
• People currently taking another investigational (experimental) drug within 28 days or 5 half-lives before starting the trial (whichever is shorter)
• People who are unable to stop taking certain prescription or non-prescription medicines, foods, or herbal supplements that strongly or moderately affect how the body processes the trial drug, at least 14 days before starting (confirm with trial site)
• People who have previously been treated with ZN-c3 or any other WEE1 inhibitor, ATR inhibitor, PKMYT1 inhibitor, or CHK1/2 inhibitor (these are specific types of targeted drugs — confirm with trial site)
• People with brain metastases (cancer spread to the brain) that are causing symptoms or require immediate treatment; people with brain metastases that are not causing symptoms may still be considered
• People with significant heart failure (classified as NYHA Class II to IV)
• People with serious medical or psychiatric conditions that could increase risk or affect the trial results
• People who have had a recent kidney injury requiring treatment or intravenous fluids in the past 14 days, or who have a urinary catheter or kidney drainage tube in place
• People with significant digestive problems, including an inability to swallow tablets, a need for intravenous nutrition, an active stomach ulcer, ongoing significant diarrhoea or vomiting, or prior bowel surgery that affects how medicines are absorbed
• People with an active, uncontrolled infection; people who have been treated for an infection must have completed treatment and been free of fever for at least 7 days before starting the trial
• People with evidence of a bowel blockage, a recent hospitalisation for small bowel obstruction within 3 months, or repeated procedures to drain fluid from the abdomen or chest within 6 weeks before starting the trial
• People with unresolved side effects from previous treatments that are still at a significant level (Grade 2 or higher), with some exceptions such as mild nerve-related symptoms, hair loss, or skin colour changes
• People who are pregnant or breastfeeding, or people of childbearing potential who have a positive pregnancy test within 14 days before starting the trial
• People with a history of another cancer within the past 2 years, unless it was fully treated by surgery alone and there has been no sign of disease since (certain low-risk cancers may be excepted — confirm with trial site)
• People who are known to have a weakened immune system or who are HIV-positive and on antiretroviral therapy
• People with known active hepatitis B or hepatitis C infection
• People with prior wide-field radiation treatment that covered 20% or more of the bone marrow
• People considered unsuitable for the trial by the treating doctor

Important: Always verify eligibility with the trial site directly before applying.